Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline | Zendy

YuPei Chen | Zendy; Nofisat Ismaila | Zendy; Melvin L.K. Chua | Zendy; A. Dimitrios Colevas | Zendy; Robert I. Haddad | Zendy; Shao Hui Huang | Zendy; Joseph Wee | Zendy; Alexander C. Whitley | Zendy; Junlin Yi | Zendy; Sue S. Yom | Zendy; Anthony T.�C. Chan | Zendy; Chaosu Hu | Zendy; Jinyi Lang | Zendy; QuynhThu Le | Zendy; Anne W.M. Lee | Zendy; Nancy Y. Lee | Zendy; JinChing Lin | Zendy; Brigette Ma | Zendy; T. J. Morgan | Zendy; Jatin P. Shah | Zendy; Ying Sun | Zendy; Jun Ma | Zendy

Open Access

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Author(s) -

YuPei Chen,

Nofisat Ismaila,

Melvin L.K. Chua,

A. Dimitrios Colevas,

Robert I. Haddad,

Shao Hui Huang,

Joseph Wee,

Alexander C. Whitley,

Junlin Yi,

Sue S. Yom,

Anthony T.�C. Chan,

Chaosu Hu,

Jinyi Lang,

QuynhThu Le,

Anne W.M. Lee,

Nancy Y. Lee,

JinChing Lin,

Brigette Ma,

T. J. Morgan,

Jatin P. Shah,

Ying Sun,

Jun Ma

Publication year - 2021

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.03237

Subject(s) - medicine , guideline , nasopharyngeal carcinoma , radiation therapy , oncology , stage (stratigraphy) , evidence based medicine , randomized controlled trial , systematic review , chemoradiotherapy , evidence based practice , family medicine , medline , head and neck cancer , intensive care medicine , alternative medicine , pathology , paleontology , political science , law , biology

PURPOSE The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma (NPC).METHODS The Chinese Society of Clinical Oncology (CSCO) and ASCO convened an expert panel of radiation oncology, medical oncology, surgery, and advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2020. Outcomes of interest included survival, distant and locoregional disease control, and quality of life. Expert panel members used this evidence and informal consensus to develop evidence-based guideline recommendations.RESULTS The literature search identified 108 relevant studies to inform the evidence base for this guideline. Five overarching clinical questions were addressed, which included subquestions on radiotherapy (RT), chemotherapy sequence, and concurrent, induction, and adjuvant chemotherapy options.RECOMMENDATIONS Evidence-based recommendations were developed to address aspects of care related to chemotherapy in combination with RT for the definitive-intent treatment of stage II to IVA NPC. Additional information is available at www.asco.org/head-neck-cancer-guidelines .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research